News

Enlarge image

FundingUK

Wellcome Trust invests a £200m VC

04.01.2013 - The Wellcome Trust’s new venture capital unit Syncona Partners LLC pours £200m into early stage healthcare start ups.

The world’s second largest charity plans to invest between £1m-£20m in each of its future portfolio companies as announced last spring. According to Wellcome's annual report last month, Syncona has already made one investment. The directly owned and managed investment firm combines the trust’s experience in the health and biotechnology sectors with its investment expertise. While Syncona offers a new source of finance and guidance for healthcare businesses at an early stage of their development, the trust hopes to make some return on investment to fuel its pipeline of charitable projects.

“We expect to play our part in building successful businesses based upon innovation within the life science and health-care industry,” Syncona Chief Executive Officer Martin Murphy said in a statement. According to the Trust’s annual report, its role is becoming an increasingly global one. It disclosed that UK assets now account for a mere 6% of its £14.5bn investment portfolio, down from 13% in 2009 and 33% in 2006. Hence the portfolio “has hardly suffered from the underperformance of European assets in the financial crisis.” The influential investor has also cut its assets in Europe, with the proportion of its portfolio invested in the continent falling to 13% (2009: 22%; 2006: 48%). The charity said that it envisaged better returns from faster-growing nations in Asia and Latin America.

© eurobiotechnews.eu/bk

http://www.european-biotechnology-news.com/news/news/2013-01/wellcome-trust-invests-a-pound200m-vc.html

CommercialisationEU

10.02.2016 In future, meds will come in packages sporting a unique barcode and an anti-tampering device. These measures are part of the EU’s new regulation to safeguard against falsified medicines.

Clinical ResearchFrancePortugalEU

05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.

M&ASwitzerland

04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.

FinancingEUUKBelgium

01.02.2016 Newly formed Medicxi Ventures, a life sciences-dedicated VC firm based in London, Geneva and Jersey, has closed a €210m investment fund to reinvest in European early-stage assets.

ResearchUKEU

01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.

M&ASwedenIceland

28.01.2016 Swedish infectious disease specialist Enzymatica has bagged Icelandic company Zymetech, who produces the patent-protected enzyme used in Enzymatica’s own common cold blocker ColdZyme.

R&DUK

27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.

Clinical TrialsGermany

25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.

AMREU

21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.

M&AFinland

19.01.2016 Biotie Therapies has long been expanding its business in the US. Now, the Finnish company is set to be taken over by US company Acorda Therapeutics, which is paying €321m for the shares.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • DIAMYD MEDICAL -B- (S)5.10 SEK20.00%
  • KARO BIO (S)29.30 SEK19.59%
  • PLETHORA (UK)2.75 GBP4.96%

FLOP

  • SWEDISH ORPHAN BIOVITRUM (S)12.45 USD-23.38%
  • BIOTIE THERAPEUTICS (FI)0.14 EUR-22.22%
  • PAION (D)1.08 EUR-13.60%

TOP

  • VERONA PHARMA (UK)3.40 GBP30.8%
  • IXICO (UK)35.75 GBP21.2%
  • SAREUM HOLDINGS (UK)0.28 GBP12.0%

FLOP

  • PAION (D)1.08 EUR-56.3%
  • BIONOR PHARMA (N)0.79 NOK-51.8%
  • PROTHENA PLC (IE)30.12 USD-41.6%

TOP

  • KARO BIO (S)29.30 SEK3755.3%
  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • NICOX (F)6.45 EUR224.1%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)8.70 SEK-86.1%
  • BIOTEST (D)13.81 EUR-85.2%
  • EVOCUTIS (UK)0.08 GBP-69.2%

No liability assumed, Date: 11.02.2016